Brad Penenberg, MD
Orthopaedic Surgery · Beverly Hills, CANPI 1831122266
Payments from drug & device makers
What this record shows
This record is dominated by royalties or licence payments: $3,905,124 of the $3,997,735 with a category attached, or 97.7%. Zimmer Biomet accounts for 60.6% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2021 at $1,056,877 and has fallen 90.2% since, to $103,369 in 2025. Among orthopaedic surgery clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 276 payments — averaging $14,485 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Zimmer Biomet$2.4M
- Microport Orthopedics Inc$1.2M
- Medacta USA, Inc.$255K
- UOC USA Inc$69K
- Smith+Nephew$5K
- Shalby Advanced Technologies, Inc.$527
- plus $2K from 15 others
What the payments were for
- Royalty or licence$3,905,12498%
- Consulting fees$70,6572%
- Travel & lodging$13,1620%
- Food & beverage$8,6040%
- Education$1880%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Zimmer Biomet | 74 | $2,421,994 |
| Microport Orthopedics Inc | 50 | $1,244,944 |
| Medacta USA, Inc. | 24 | $255,042 |
| UOC USA Inc | 44 | $68,562 |
| Smith+Nephew | 23 | $4,914 |
| Shalby Advanced Technologies, Inc. | 3 | $527 |
| Stryker | 16 | $512 |
| Siemens Medical Solutions USA, Inc. | 3 | $367 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $196 |
| Lima USA, Inc. | 1 | $141 |
| Zyla Life Sciences, Inc. | 8 | $101 |
| Fidia Pharma USA Inc. | 9 | $95 |
| Intellijoint Surgical Inc. | 1 | $79 |
| Biocomposites Inc | 2 | $75 |
| Think Surgical, Inc. | 1 | $54 |
| Biodelivery Sciences International, Inc. | 2 | $36 |
| Merz Pharmaceuticals, LLC | 1 | $29 |
| Pfizer | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Assertio Therapeutics, Inc. | 1 | $15 |
| AstraZeneca | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Persona$2,162,353
- MPO Hip System$1,244,944
- AMISTEM$242,776
- A.L.P.S.$174,140
- Persona Partial Knee System$82,526
- Resolve$19,263
- U2, PSA, UTF, UTS, CONFORMITY, U-MOTION II, U-Star II$16,846
- QUADRA$10,653
- U2, Conformity, U-Motion II and USTAR II$7,402
- MHR$6,336
- Medial Pivot$4,860
- Conformity and U-Motion II$3,000
- Conformity, U-Motion II and USTAR II$2,880
- Journey II XR$1,861
- U-Motion II, Conformity, U2, AiO, UTF, UTS, MDT$1,800
- Navio Surgical System$1,350
- GMK SPHERE$1,043
- Walter$1,000
- POLARSTEM$555
- CONSENSUS KNEE SYSTEM$481
How this compares
$3,997,735 in reported general payments places this provider in the 95th percentile of 1,808 orthopaedic surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 13 | $1,833 |
| Celecoxib | 74 | $1,632 |
| Lidocaine | 12 | $737 |
| Gabapentin | 86 | $565 |
| Amoxicillin | 147 | $378 |
| Meloxicam | 87 | $294 |
| Clindamycin Hcl | 39 | $276 |
| Tramadol Hcl | 18 | $55 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $22 | $1,83313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,808 orthopaedic surgery providers in California.
Other orthopaedic surgery in Beverly Hills
- Bradford HackArcadia$18.3M
- Robert GorabOrange$13.6M
- Kelly VinceLos Angeles$9.6M
- Stephen HowellSacramento$9.4M
- Thomas CoonRed Bluff$9.2M
- Nirav AminPlacentia$5.6M
- Tom NorrisSan Francisco$5.3M
- Jay LiebermanLos Angeles$4.8M
- Peter NewtonSan Diego$4.2M
- Sigurd BervenSan Francisco$4.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.